A5012015082- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Rheumatoid Arthritis Research and Therapies
- Acute Lymphoblastic Leukemia research
- Lysosomal Storage Disorders Research
- Immunodeficiency and Autoimmune Disorders
- Spondyloarthritis Studies and Treatments
- Inflammasome and immune disorders
- Kawasaki Disease and Coronary Complications
- Childhood Cancer Survivors' Quality of Life
- Otitis Media and Relapsing Polychondritis
- Trypanosoma species research and implications
- Systemic Lupus Erythematosus Research
- Urticaria and Related Conditions
- Nutrition and Health Studies
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Glycogen Storage Diseases and Myoclonus
- Autoimmune Bullous Skin Diseases
- Renal Diseases and Glomerulopathies
- Health Systems, Economic Evaluations, Quality of Life
- Musculoskeletal synovial abnormalities and treatments
- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Biosimilars and Bioanalytical Methods
Andrzej Frycz Modrzewski Krakow University
2018-2025
Uniwersytecki Szpital Dziecięcy
2015-2024
Wojewódzki Szpital Specjalistyczny we Wrocławiu
2022
St. Louis Children's Hospital
2014-2018
Jagiellonian University
2016
Bambino Gesù Children's Hospital
2014
Roche (United Kingdom)
2014
Boston Children's Hospital
2014
Great Ormond Street Hospital
2014
University College London
2014
Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA; treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA.We randomly assigned 112 children, 2 to 17 years age, with active JIA (duration ≥6 months and inadequate responses nonsteroidal antiinflammatory drugs glucocorticoids) anti-interleukin-6 receptor antibody tocilizumab (at dose 8 mg per kilogram body weight if was ≥30 kg or 12 <30 kg) placebo given intravenously every weeks during...
Objective To evaluate the interleukin-6 receptor inhibitor tocilizumab for treatment of patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). Methods This three-part, randomised, placebo-controlled, double-blind withdrawal study ( NCT00988221 ) included who had active pcJIA ≥6 months and inadequate responses to methotrexate. During part 1, received open-label every 4 weeks (8 or 10 mg/kg body weight (BW) <30 kg; 8 BW ≥30 kg). At week 16, ≥JIA-American College...
<h3>Abstract</h3> Antifungal resistance in pathogenic fungi is a growing global health concern. Non-pathogenic laboratory strains of <i>Saccharomyces cerevisiae</i> are useful model for studying mechanisms antifungal that relevant to understanding the same processes fungi. We developed series lab modules which high school students used experimental evolution study by isolating azole-resistant <i>S. and examining genetic basis resistance. All 99 sequenced clones from these experiments...
Treatment options in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic (JPsA) are currently limited. This trial aimed to demonstrate the efficacy safety of secukinumab active ERA JPsA inadequate response conventional therapy.In this randomised, double-blind, placebo-controlled, treatment-withdrawal, phase 3 trial, biologic-naïve (aged 2 <18 years) disease were treated open-label subcutaneous (75/150 mg <50/≥50 kg) treatment period (TP) 1 up week 12, idiopathic (JIA)...
Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and a leading cause of childhood disability. The objective this study was to characterize PK, safety, taste acceptability tofacitinib in patients with JIA. This Phase 1, open-label, multiple-dose (twice daily [BID] for 5 days) active (≥ joints) polyarticular course JIA conducted from March 2013–December 2015. Patients were allocated one three age-based cohorts: Cohort 12 < 18 years; 2, 6 3, 2 years....
We present a 3-year follow-up of boy with mucopolysaccharidosis type II (MPS II) who had idursulfase therapy initiated at the age 3 months and compare his clinical course to healthy twin brother.Detailed anthropometric features, ultrasound studies liver spleen volumes, echocardiography audiological examinations, psychological tests, joint range motion (ROM) skeletal radiographs were monitored.After years treatment, patient has not developed any manifestations MPS II. He did develop coarse...
Abstract To assess the incidence and prevalence of rheumatoid arthritis (RA) in Poland for period 2013–2021, total dependent on gender, age, region serological status. Information reported National Health Fund (NHF) health services reimbursed prescriptions were used, defining an RA patient as a person who had at least two visits different quarters with ICD-10 code M05 or M06 same time filled one prescription drug whose active substance is methotrexate, sulfasalazine, leflunomide was treated...
To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related (ERA), psoriatic (PsA) METHODS: Patients who completed 2-year, open-label, phase III CLinical Study In Pediatric Etanercept for Treatment ERA, PsA, Extended Oligoarthritis (CLIPPER) were allowed to enroll its 8-year long-term extension (CLIPPER2). Children received ETN at a once-weekly dose 0.8 mg/kg, up maximum 50 mg/week. Efficacy...
The growing use of biological drugs in immune-mediated chronic diseases has undoubtedly revolutionized their treatment. Yet, the topic vaccinations this group patients still raises many concerns and implies therapeutic problems that require discussion standardization management. aim literature review is to present current knowledge regarding safety efficacy dermatological rheumatological treated with JAK inhibitors. Additionally, article provides recommendation from experts Polish...
Abstract Background Diagnostic pathways for patients with juvenile idiopathic arthritis (JIA) have gradually improved over time. Provider practice has also shifted towards goal-oriented treatment disease-modifying drugs (DMARDs) that together may changed the epidemiologic landscape of JIA. Methods Public healthcare utilization records from National Health Fund (NHF) were screened between 2010 and 2022. For individuals aged < 16 years, we utilized a narrow JIA case definition combining...
Background: Only few studies have compared plantar and dorsal incisions in the treatment of primary intermetatarsal Morton's neuroma (PIMN). The results guidelines are, however, still controversial, mainly due to confounding factors study design. present is an attempt systematically compare two approaches. Materials Methods: With a 2- 5-year followup, we retrospectively 125 patients (132 feet) with PIMN. All specimens had histology assessments. Longitudinal were performed by one experienced...
To report the 2-year efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (JIA).Patients ages 2-17 years active JIA, whom treatment methotrexate was unsuccessful, received 16 weeks open-label intravenous TCZ part 1 (once every 4 weeks: 8 mg/kg or 10 for body weight [BW] <30 kg; BW ≥30 kg). Assessments were based on JIA-American College Rheumatology (ACR) response (defined as percentage improvement ≥3 6 JIA core variables [CRVs])....
What's new?The biosimilars contribute to meaningful savings for healthcare systems in Europe.Despite this, disparities access affordable biologics and overall innovative treatments still exist.Data on whether the saved funds allocation is most beneficial from patients' perspective are missing.This nationwide study provides a multilevel analysis of therapies RMDs, with less costly TNFis group treated as benchmark.Within timeframe, bDMARDs/JAKis increased, but remains relatively low.Less...
Human leukocyte antigen B27 (HLA-B27) is considered as a risk factor for development of juvenile idiopathic arthritis (JIA). The aim this study was to analyse the prevalence HLA-B27 in JIA categories and its influence on disease onset response conventional therapy.The retrospective analysis included 461 unselected children with hospitalized single reference rheumatology centre between July 2007 June 2012. diagnosis based criteria by International League Association Rheumatology. determined...
To evaluate the long-term safety and efficacy of etanercept treatment in Polish patients with juvenile idiopathic arthritis (JIA).The study involved patients, fulfilling JIA criteria International League Associations Rheumatology (ILAR), who were started on therapy after methotrexate other synthetic disease-modifying antirheumatic drugs (DMARDs) had proven ineffective. Patient data collected an electronic registry. Disease improvement was assessed based Giannini's criteria.The statistical...
Pachydermodactyly (PDD) is a rare and benign form of digital soft tissues fibromatosis, which affects the skin fingers. The disorder characterized by asymptomatic, symmetric, progressive tissue swelling proximal interphalangeal (PIP) joints etiology disease remains unknown. It usually acquired, even though there are some publications that document family cases. mainly adolescent men. We report two boys with bilateral PIP fingers subcutaneous thickening. Based on clinical manifestations,...
Abstract Objectives CLIPPER2 was an 8-year, open-label extension of the phase 3b, 2-year CLIPPER study on safety and efficacy etanercept in patients with JIA, categorized as extended oligoarticular arthritis (eoJIA), enthesitis-related (ERA) or PsA. Methods Participants eoJIA (2–17 years old), ERA PsA (each 12–17 old) who received ≥1 dose (0.8 mg/kg weekly; maximum 50 mg) could enter CLIPPER2. Primary end point occurrence malignancy. Efficacy assessments included proportions achieving JIA...
Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is an X-linked, recessive, lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase. Early bone involvement leads to decreased growth velocity and short stature in nearly all patients. Our analysis aimed investigate the effects enzyme replacement therapy (ERT) with idursulfase (Elaprase) on young patients mucopolysaccharidosis II. Analysis longitudinal anthropometric data MPS (group 1, n = 13) who started ERT before 6...
<h3>Background</h3> The IL-6 receptor inhibitor TCZ was investigated for the treatment of sJIA patients (pts) in ongoing 3-part, 5-y, phase 3 TENDER study. <h3>Objectives</h3> Long-term efficacy and safety are presented. <h3>Methods</h3> 112 pts 2-17 y with active ≥6 mo were randomised 2:1 to (8 mg/kg if body weight ≥30 kg; 12 <30 kg, n=75) or placebo (n=37) every 2 wks part 1; all received open-label (to 104 wks). Oral corticosteroid (CS) tapering permitted according pre-defined...